NEWS

August 8, 2022

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

June 30, 2022

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

June 16, 2022

Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

February 3, 2022

Healthcare Royalty Partners Details HCR’s Record For Royalty Receipts and Market Activity in 2021 Year In Review

September 30, 2021

Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners^® for Up to $125 Million

August 26, 2021

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

June 24, 2021

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

May 5, 2021

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases

March 31, 2021

Aptevo Therapeutics Announces Sale of Ruxience Royalty Payments to HCR

March 29, 2021

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma